RE:RE:RE:Q2 EarningsCADInvestor12 wrote: Seeing Tilray's international medical cannabis sales drop QoQ is concerning since they operate in the same countries as MPL. We'll see what ends up happening but I'm getting restless while waiting lol.
The LABS CC will simply refer to 'market lumpiness' as the reason. Strachan loves this since it doesn't mean a damn thing apart from they have no idea what happened and ultimately where they're going.
We can hope that perhaps the LABS market(s)/partners were a bit more mature than Tilray say and they avoided the weakening somewhat, but of course Tilray gives them a big green light to blame jurisdication dynamics on a potential poor performance.
As I said earlier, Drobinonol alone should make normal international sales look paltry by comparison. If they didn't hit that out of the park, then this is one question that needs to be asked certainly.